Shares in Novo Nordisk were up nearly 12% today – hiking its valuation to more than $280 billion – after it reported new clinical data with one of its obesity drug candidates. The new results ...

Novo Nordisk's stock (NVO) rose more than 8% in Friday trading on news that the company's latest weight-loss product delivered favorable results. The new drug, amycretin, similar to the company's ...

"Novo Nordisk reports topline data from Phase Ib/IIa trial of weight loss therapy" was originally created and published by Clinical Trials Arena, a GlobalData owned brand. The information on this ...

Novo Nordisk (NVO) shares traded sharply higher ... caused up to 22% of weight loss over 36 weeks in a Phase 1b/2a trial. Citing topline data from the trial, the company added that amycretin ...

Investing.com -- Shares of pharmaceutical giant Eli Lilly (NYSE:LLY) edged down 1.2% in premarket trading following announcements from competitor Novo Nordisk ... of the new data, stating ...

Novo estimates that CKD affects some 37 million adults in the U.S., with that number likely to rise in the coming years. The condition is also a common complication of Type 2 diabetes, cropping up ...

Profit and prosper with the best of expert advice - straight to your e-mail. Novo Nordisk has underperformed the broad market on the price charts over the past 12 months, down 17% vs the S&P 500's ...

Novo Nordisk announced phase 1b/2a clinical trial results for amycretin this morning. Patients taking the GLP-1 drug lost an average of 9.7% of their weight in 36 weeks. This is the best news Novo ...

Novo Nordisk's stock (NVO) rose more than 8% in Friday trading on news that the company's latest weight-loss product delivered favorable results. The new drug, amycretin, similar to the company's ...

Novo Nordisk (NVO) said its popular diabetes drug Ozempic, also known as semaglutide, has been approved to reduce the risk of kidney disease worsening, kidney failure, and death from ...